Oxford BioDynamics Plc (OBD) has announced that Vulpes Testudo Fund, controlled by Non-Executive Director Stephen Diggle, has sold 125,000 Ordinary Shares of 1 pence each at an average price of 33.9p. Following this transaction, Diggle is interested in a total of 27,431,756 shares, representing approximately 13.56% of the company's current issued share capital.

OBD is a global biotechnology company that develops and commercializes precision medicine tests for life-changing diseases. Its flagship products include the EpiSwitch CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch PSE (EpiSwitch Prostate Screening test) blood tests. The CiRT test is a predictive immune response profile for immuno-oncology checkpoint inhibitor treatments, while the PSE test boosts the predictive accuracy of a PSA test for prostate cancer.

In addition to these tests, OBD has also launched the EpiSwitch CST (Covid Severity Test) and the EpiSwitch Explorer Array Kit, a microarray kit for high-resolution 3D genome profiling and biomarker discovery. The company's product portfolio is based on its proprietary 3D genomic biomarker platform, EpiSwitch, which can build molecular diagnostic classifiers for various indications.

OBD has participated in partnerships with major pharmaceutical companies and institutions, including Pfizer, Roche, Biogen, and Mayo Clinic. The company has a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, and bioinformatic tools for 3D genomics.

OBD is headquartered in Oxford, UK, and is listed on AIM of the London Stock Exchange. It also has offices and laboratories in Gaithersburg, MD, USA, and Penang, Malaysia.